Results 101 to 110 of about 389,573 (268)

Lymphoid‐Tissue‐on‐Chip Recapitulates Human Antibody Responses In Vitro

open access: yesAdvanced Science, EarlyView.
The presented lymphoid‐tissue‐on‐chip system allows culture of primary human tonsil cells at organotypic high density under perfusion for up to 4 weeks, emulates immune response to soluble vaccines and vaccination via peripheral antigen‐presenting cells and represents a useful tool to assess cellular interactions during homeostasis, immune responses ...
Claudia Teufel   +15 more
wiley   +1 more source

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

open access: yesVaccines
Concomitant administration may improve vaccination rates. This analysis of a phase 1/2 randomized study included 1073 healthy ≥65-year-olds who previously received ≥3 mRNA COVID-19 vaccine doses.
Joel M. Neutel   +17 more
doaj   +1 more source

Small Extracellular Vesicles‐Derived Circ6718 Unlocks Stromal Remodeling and Serves as a Biomarker in Gastric Cancer

open access: yesAdvanced Science, EarlyView.
sEVs‐circ6718 serves as a promising serum biomarker for gastric cancer early diagnosis and prognosis, promoting malignant transformation in gastric cancer cells and GC‑MSC differentiation into CAFs. sEVs‑circ6718 holds potential as a biomarker for the early diagnosis and prognostic assessment of gastric cancer.
Fan Zhang   +7 more
wiley   +1 more source

Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells

open access: yesAdvanced Science, EarlyView.
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin   +12 more
wiley   +1 more source

A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants

open access: yesInternational Journal of Infectious Diseases
Objectives: Safety and immunogenicity evaluation of a 4-dose series with 20-valent pneumococcal conjugate vaccine (PCV20). Methods: This phase 3, double-blind study randomized healthy Japanese infants to receive 4 doses (3 infant doses, 1 toddler dose ...
Yasunori Ishihara   +12 more
doaj   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu   +4 more
wiley   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang   +8 more
wiley   +1 more source

Transdermal Delivery of an mRNA‐Liposome Vaccine via Dissolving Microneedle to Preserve Vaccine Activity and Enhance Immune Activation

open access: yesAdvanced Science, EarlyView.
An mRNA‐liposome vaccine via dissolving microneedles (ML‐DMN) enables efficient skin‐targeted delivery while preserving mRNA integrity and allowing sustained antigen expression. Unlike intramuscular (IM) injection, ML‐DMN engages skin‐resident immune cells, activates antigen‐presenting cells (APCs), and induces strong T cell and cytokine responses at ...
Jeehye Nam   +9 more
wiley   +1 more source

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial

open access: yesVaccines
We report neutralization titer data against contemporary SARS-CoV-2 sublineages from an ongoing, phase 2/3, open-label, clinical trial of a single dose (30 μg) of an Omicron XBB.1.5-adapted BNT162b2 monovalent mRNA vaccine.
Juleen Gayed   +11 more
doaj   +1 more source

Pneumococcal vaccine development

open access: yesExpert Review of Vaccines, 2004
A 7-valent pneumococcal conjugate vaccine has demonstrated an impact on pneumococcal bacteremia in the immunized pediatric population, extending to nonimmunized adults via herd immunity. A considerable reduction of all-cause pediatric pneumonia has also been found.
openaire   +2 more sources

Home - About - Disclaimer - Privacy